Research programme: anti-tau therapeutic vaccines - AC Immune/Janssen

Drug Profile

Research programme: anti-tau therapeutic vaccines - AC Immune/Janssen

Latest Information Update: 13 Feb 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Janssen Pharmaceuticals
  • Class Alzheimer vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Neurodegenerative disorders

Most Recent Events

  • 12 Jan 2015 AC Immune and Janssen Pharmaceuticals agree to co-develop anti-tau therapeutic vaccine for Neurodegenerative diseases
  • 12 Jan 2015 Early research in Neurodegenerative disorders in Germany (unspecified route)
  • 12 Jan 2015 Investigation in Neurodegenerative disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top